Beanlands R S, Muzik O, Mintun M, Mangner T, Lee K, Petry N, Hutchins G D, Schwaiger M
Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor 48109-0028.
J Nucl Med. 1992 May;33(5):684-90.
Copper-62-labeled pyruvaldehyde bis(N-4-methylthiosemicarbazone) copper(II) (PTSM) is a generator-produced myocardial perfusion tracer. Animal studies have shown high myocardial tissue extraction and prolonged retention. The aim of this study was to define myocardial kinetics of 62Cu-PTSM and to determine its suitability for evaluating myocardial perfusion at rest and during pharmacological vasodilation in human subjects. In six healthy volunteers, 62Cu-PTSM was administered at baseline and during a 6-min adenosine infusion (140 micrograms/kg/min). Dynamic PET imaging with high temporal resolution was performed over 20 min. Good image quality was observed at rest and following adenosine. Myocardial kinetics demonstrated prolonged tissue retention with a clearance half-life of 105 +/- 49 min at rest and 101 +/- 65 min following adenosine (p = ns). Copper-62-PTSM tissue retention was quantified and showed only a 1.97-fold increase from rest to adenosine studies. This suggests attenuation of tracer retention at high flow rates. Copper-62-PTSM represents a promising new radiopharmaceutical for the evaluation of myocardial perfusion in the human heart.
铜-62标记的丙酮醛双（N-4-甲基硫代半卡巴腙）铜（II）（PTSM）是一种由发生器产生的心肌灌注显像剂。动物研究表明其心肌组织摄取率高且滞留时间长。本研究的目的是确定62Cu-PTSM的心肌动力学，并确定其在评估人体静息和药物性血管扩张期间心肌灌注方面的适用性。在6名健康志愿者中，在基线时以及在6分钟腺苷输注（140微克/千克/分钟）期间给予62Cu-PTSM。在20分钟内进行具有高时间分辨率的动态PET成像。静息时和腺苷输注后观察到良好的图像质量。心肌动力学显示组织滞留时间延长，静息时清除半衰期为105±49分钟，腺苷输注后为101±65分钟（p=无显著性差异）。对铜-62-PTSM的组织滞留进行了定量分析，结果显示从静息研究到腺苷研究仅增加了1.97倍。这表明在高流速下示踪剂滞留有所减弱。铜-62-PTSM是一种有前景的新型放射性药物，可用于评估人体心脏的心肌灌注。
